Mylan Pharmaceuticals launches generic hepatitis C drug MyHep in India

NEW DELHI: Drugmaker Mylan Pharmaceuticals today launched generic Sofosbuvir tablets, indicated for the treatment of chronic hepatitis C, in the country.

US-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, it said in a statement.

"The launch of Mylan's MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option," Mylan President Rajiv Malik said.

MyHep is an important addition to Mylan's business in India and is sold as part of Hepato Care segment.

The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen.

The disease affects more than 100 million people in the developing world, including, around 12 million people, who are chronically infected with hepatitis C in India.

In September 2014, Mylan had entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir in 91 developing markets, including India.